Cathie Wood's ARK ETF buys AMD and sells Tempus stock

Cathie Wood's ARK ETFs made notable portfolio adjustments on September 16, 2025, reinforcing their focus on disruptive innovation across tech and biotech sectors. Significant purchases included $8.23 million in crypto exchange Bullish (BLSH), $7.12 million in Intellia Therapeutics (NTLA), and $4.17 million in Advanced Micro Devices (AMD), alongside other investments in gene-editing and travel. Concurrently, ARK divested a substantial $14.26 million from Tempus AI (TEM) and $0.86 million from Roku (ROKU), indicating strategic reallocations within its actively managed funds.

Analysis

ARK Invest's trading activity on September 16, 2025, reveals a significant capital reallocation reinforcing its high-conviction theses in biotechnology and digital assets, funded by a major divestment in the AI healthcare space. The firm executed its largest purchase in the cryptocurrency exchange Bullish (BLSH), acquiring 161,183 shares for $8.23 million, underscoring a continued bullish stance. This was complemented by substantial investments in the gene-editing sector, including a $7.12 million purchase of Intellia Therapeutics (NTLA) and smaller additions in CRISPR Therapeutics (CRSP) and Beam Therapeutics (BEAM), indicating a clustered bet on genomic innovation. Further buys in Advanced Micro Devices (AMD) for $4.17 million and Airbnb (ABNB) for $3.17 million align with ARK's established focus on semiconductors and disruptive travel technology. Conversely, the most notable move was the sale of 167,598 shares of Tempus AI (TEM) for $14.27 million, a move that extends a selling pattern from the previous week and signals a decisive strategic shift away from the position. A smaller sale of Roku (ROKU) for $0.86 million suggests a minor portfolio trim rather than a change in fundamental thesis.

Key Decisions for Investors

• Investors should note the significant and ongoing divestment from Tempus AI (TEM), which serves as a strong negative signal from a key active manager and may warrant a re-evaluation of exposure to the stock.
• ARK's concentrated buying across multiple gene-editing companies, including Intellia (NTLA), CRISPR (CRSP), and Beam (BEAM), suggests a high-conviction view on the sub-sector, presenting a potential area for thematic investment focus.
• The substantial capital deployment into Bullish (BLSH) reinforces ARK's bullish thesis on the crypto exchange space, suggesting followers of this theme should monitor the position as a core holding for the firm.
• The contrast between the major exit from TEM and the minor trim in Roku (ROKU) highlights the importance of analyzing the scale of trades to differentiate between strategic liquidations and routine portfolio rebalancing.